Safety and Efficacy of Patient Controlled Analgesia Using the Sublingual Sufentanil Tablet System (SSTS) in a Fast Track Rehabilitation Program After Total Knee Arthroplasty

Total knee arthroplasty is one of the most common major procedures performed today with a significant impact on health care budgets. Fast track rehabilitation programmes are being developed to control hospitalization costs associated with this procedure. Interestingly, such pathway controlled fast track programs also appear to enhance functional recovery and to reduce complications. These beneficial effects are mainly attributed to the practice of rapid mobilization and early intensified physiotherapy which can only be achieved with effective analgesic techniques.

Current PCA techniques - predominantly morphine based - are the gold standard for this purpose but they involve intravenous access and a programmable computer system requiring close supervision. Reported shortcomings are systems failure leading to analgesic gaps, drug errors and restrictions in mobility since patients are tethered to IV poles. The SSTS may overcome these limitations because the opioid used, sufentanil, has a more predictable time of onset, the delivery system does not require programming, and the device does not limit patient's mobility. It retains the benefits of potent analgesia as well as patient empowerment and is particularly suited to target the analgesic effect precisely to the level required in physiotherapeutic sessions.

The present study will test the hypothesis that SSTS is an efficient and safe analgesic technique allowing fast track rehabilitation after total knee arthroplasty in a prospective cohort design.

The study will focus on the efficiency of STSS which is defined as 75% or more of the treated patients proves NRS score less than 4 during 48 hours postoperatively, additionally to the basic pain treatment (paracetamol and NSAID).

The STSS will allow the patient tot take a maximum of 3 doses in one hour. Treatment with the STSS is continued over a period of 48 hours or if necessary up to 72 hours.

During this period the patients pain en parameters will be monitored closely.

The maximum administered total dose of Zalviso will not exceed 1.2mg.

Inclusion criteria

• Male and female patients between 40-75 years old
• Able to give consent
• Scheduled of elective knee arthroplasty with a fast rehabilitation program
• Able to understand PCA principle and capable to operate SSTS device

Exclusion criteria

• Outside age range
• Contra indication for anti-inflammatory drugs
• Revision total knee arthroplasty
• history of substance abuse,
• pregnancy,lactation
• severe hepatic impairment (INR>1,5 and/or AST/ALT above x3 highest normal value),
• sleep apnea (documented by sleep laboratory study),
• severe chronic kidney disease (eGFR<30 mL/min/1.73 m2),
• severe and very severe COPD (GOLD III and IV)
• opioid tolerance (use of >15mg oral morphine equivalent per day within the past 3 months),
• chronic pain conditions necessitating gabapentinoids, steroids or anti-inflammatory drugs
• hypersensitivity to sufentanil
• significant respiratory depression (need for outpatient supplemental oxygen therapy),
• participation in another clinical trial